The present invention pertains to a compound that has an excellent retinoic acid receptor-related orphan receptor γt inhibitory effect, or a pharmaceutically acceptable salt thereof. Provided is a compound represented by general formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, R1 is a C1-C6 alkyl group, a C3-C6 cycloalkyl group, or a phenyl group. R2 is a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or the like. R3 is a hydrogen atom, a C2-C7 carboxyalkyl group, or a hydroxyl group. R4 is a halogen atom or a C1-C6 alkyl group. R5 is a hydrogen atom or a C1-C6 alkyl group. R6 is a hydrogen atom, a halogen atom, or a C1-C6 alkyl group. R7 is a hydrogen atom, a halogen atom, or the like. R8 is a hydroxyl group, a C1-C6 alkoxy group, a mono-C1-C6 alkylamino group, or the like. L is a single bond, a methylene group, or an oxygen atom. E is a phenylene group optionally substituted independently with one or two groups selected from halogen atoms, C1-C6 alkyl groups, and C1-C6 alkylsulfonyl groups, or the like. Q1 is a nitrogen atom or a group represented by the formula =CH—. Q2 is a nitrogen atom or a group represented by the formula =CH—. The group represented by the formula —U—T— is a group represented by the formula —CH2—CH2— or the like. Y is a methylene group or an oxygen atom. V is a nitrogen atom or a group represented by the formula =C(R9)—. R9 is a hydrogen atom, a C1-C6 alkyl group, or the like.)La présente invention concerne un composé qui a un excellente effet inhibiteur du récepteur orphelin γt lié au récepteur de lacide rétinoïque ou un sel pharmaceutiquement acceptable de celui-ci. Linvention concerne un composé représenté par la formule générale (I) ou un sel pharmaceutiquement acceptable de ce celui-ci. (Dans la formule, R1 est un groupe alkyle en C1-C6, un groupe cycloalkyle en C3-C6, ou un groupe phényle. R2 est un atome dhydrogène, un atome dhalogène, un groupe alkyle en C1-C6ou analogue. R3 est un atome dhydrogène, un
